Hims & Hers shares experienced a remarkable surge of up to 55% in pre-market trading on Monday following the announcement of a renewed partnership with Novo...
Hims & Hers, a prominent telehealth company, has announced a significant partnership with Novo Nordisk that will enhance its offerings in the weight loss sector. The...
Goldman Sachs has downgraded its rating for Novo Nordisk from “buy” to “neutral” following disappointing phase 3 clinical trial results for the company’s next-generation obesity medicine,...
Sun Pharmaceutical Industries, India’s largest drugmaker by revenue, has received regulatory approval to manufacture and sell semaglutide, the generic counterpart of the highly successful weight-loss medication...
The Danish drugmaker Novo Nordisk has officially launched its weight loss pill, Wegovy, in the United States as of March 15, 2024. The medication, which is...
Health Canada is currently reviewing nine submissions for generic versions of popular obesity medications, potentially paving the way for lower prices this summer. The focus is...
The oral medication Wegovy, designed for weight loss in adults, may soon be available in Canada pending approval from Health Canada. This announcement follows the recent...
Eli Lilly is positioning itself for sustained growth in the pharmaceutical sector by capitalizing on its leading role in diabetes and obesity treatments. The company is...
Negotiations to include the weight-loss drug Wegovy under Canadian public health plans have collapsed as Novo Nordisk, the Danish manufacturer, declined to pursue discussions. This development...
U.S. stock markets experienced a substantial rally during the week ending November 24, 2023, buoyed by strong performances from major healthcare companies, including Sanofi, Eli Lilly,...
